Resapp Health Ltd
ASX:RAP
Net Margin
Resapp Health Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| AU |
|
Resapp Health Ltd
ASX:RAP
|
176.2m AUD |
-282%
|
|
| US |
|
Veeva Systems Inc
NYSE:VEEV
|
47.2B USD |
27%
|
|
| US |
C
|
Cerner Corp
LSE:0R00
|
31.3B USD |
10%
|
|
| AU |
|
Pro Medicus Ltd
ASX:PME
|
33.5B AUD |
52%
|
|
| US |
|
Doximity Inc
NYSE:DOCS
|
11.5B USD |
39%
|
|
| JP |
|
M3 Inc
TSE:2413
|
1.3T JPY |
14%
|
|
| SE |
|
Sectra AB
STO:SECT B
|
71.4B SEK |
27%
|
|
| US |
W
|
Waystar Holding Corp
NASDAQ:WAY
|
6.2B USD |
3%
|
|
| US |
|
Inspire Medical Systems Inc
NYSE:INSP
|
3.8B USD |
8%
|
|
| CN |
|
Winning Health Technology Group Co Ltd
SZSE:300253
|
23.4B CNY |
3%
|
|
| IN |
I
|
Inventurus Knowledge Solutions Ltd
NSE:IKS
|
267.1B INR | N/A |
Resapp Health Ltd
Glance View
ResApp Health Ltd. engages in the research and commercial development of ResApp technology for the purpose of providing health care solutions for respiratory disease. The company is headquartered in Brisbane, Queensland. The company went IPO on 2005-01-12. The Company’s digital healthcare solutions assists doctors and patients to diagnose and manage respiratory disease. The firm has developed a platform for diagnosing respiratory disease using the sound of a patient’s cough. The platform is based on sound alone and does not require physical contact with the patient. With smartphones integrating microphones, the platform can be delivered without the need for additional hardware. The firm has developed smartphone-based machine learning algorithms, which can identify exacerbations in patients with asthma or COPD. The company also has ongoing clinical programs investigating the use of these techniques to measure exacerbation severity and lung function. The firm has developed an obstructive sleep aponia screening test that uses overnight breathing and snoring sounds recorded on a smartphone placed on the bedside table.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Resapp Health Ltd's most recent financial statements, the company has Net Margin of -282.1%.
You don't have any saved screeners yet